Caplacizumab as frontline therapy in addition to standard treatment in iTTP
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022009448
Abstract: We read with interest the meta-analysis performed by Djulbegovic et al about the use of caplacizumab as a treatment for patients with immune thrombotic thrombocytopenic purpura (iTTP). 1 We respectfully disagree with some of the… read more here.
Keywords: addition; ittp; caplacizumab frontline; standard ... See more keywords